Evidence map›Paper›PMID 34262540›Full record

ReviewFrontiers in microbiology2021

Abnormal Tryptophan Metabolism in HIV and

Xiaolei Wang, Smriti Mehra, Deepak Kaushal, Ronald S Veazey, Huanbin Xu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Metabolomics of HIV in the Modern cART Era.Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Metabolomics as a Tool to Investigate HIV/TB Co-Infection.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaolei WangDivision of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, United States.
Smriti MehraDivision of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, United States.
Deepak KaushalSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, United States.
Ronald S VeazeyDivision of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, United States.
Huanbin XuDivision of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, United States.
Tulane University · USTexas Biomedical Research Institute · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Viral Testing CoreU42OD010442 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal, Kathryn Shelton · 2012 to 2026
$35.6M
Impact of tuberculosis on the development and function of the immune system in SIV-infected infantsR01HD099857 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, WANG, XIAOLEI · 2019 to 2023
$6.9M
Myeloid and lymphoid immunity-specific mechanisms of IDO mediated immunosuppression and its reversal, during TBR01AI134245 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI Smriti Mehra · 2018 to 2026
$6.2M
Novel strategies for eliminating HIV reservoirs in lymphoid tissuesR01DE025432 · NIDCR · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2015 to 2019
$4.0M
Impact of concurrent HIV and latent TB therapies on Mtb-specific immune function-Diversity SupplementR01AI123047 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2017 to 2020
$3.9M
Early Immune Development and Function in Neonates Exposed to Maternal HIV InfectionR01AI147372 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2019 to 2021
$1.5M
Role of IDO in tryptophan pathway during Mycobacterial Tuberculosis infectionR21AI128130 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI MEHRA, SMRITI · 2017 to 2018
$449k
NIAID NIH HHS R01 AI123047NIAID NIH HHS R01 AI134245NIAID NIH HHS R01 AI147372NIAID NIH HHS R21 AI128130NICHD NIH HHS R01 HD099857NIDCR NIH HHS R01 DE025432NIH HHS P51 OD011104NIH HHS P51 OD011133NIH HHS U42 OD010442
6 · The paper itself

Abstract

Host metabolism has recently gained more attention for its roles in physiological functions and pathologic conditions. Of these, metabolic tryptophan disorders generate a pattern of abnormal metabolites that are implicated in various diseases. Here, we briefly highlight the recent advances regarding abnormal tryptophan metabolism in HIV and

Indexed as

3-dioxygenaseHIVindoleamine 2Mycobacterium tuberculosistryptophan metabolismtryptophan metabolites

Identifiers

PMID34262540
PMCPMC8273495
OpenAlexW3174190238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.